We are live on ! Find out more
JJIJ

Johnson & Johnson Innovation - JJDC Portfolio holdings

AUM $978M
1-Year Est. Return 102.17%
This Fund
S&P 500
This Quarter Est. Return
-3.55%
1 Year Est. Return
+102.17%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$772M
AUM Growth
-$3.34M
Cap. Flow
+$45.1M
Cap. Flow %
5.84%
Top 10 Hldgs %
98.86%
Holding
17
New
2
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
VOR icon
Vor Biopharma
VOR
+$45.5M
2
CALC icon
CalciMedica
CALC
+$1.06M
3
ACET icon
Adicet Bio
ACET
+$951K

Top Sells

Rank Stock Value
1
ALDX icon
Aldeyra Therapeutics
ALDX
+$2.3M
2
SENS icon
Senseonics Holdings Inc
SENS
+$94.6K

Sector Composition

Rank Sector Weight
1 Healthcare 99.84%
2 Technology 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
1
Fate Therapeutics
FATE
$269M
$279M 36.08%
3,379,064
– –
ARWR icon
2
Arrowhead Research
ARWR
$12.1B
$216M 28.01%
3,260,869
– –
PTGX icon
3
Protagonist Therapeutics
PTGX
$8.78B
$63.4M 8.22%
2,449,183
– –
LEGN icon
4
Legend Biotech
LEGN
$3.68B
$47.3M 6.12%
1,629,173
– –
VOR icon
5
Vor Biopharma
VOR
$1.08B
$46.3M 6%
+53,733
New +$45.5M
MGTX icon
6
MeiraGTx Holdings
MGTX
$1.1B
$41.8M 5.42%
2,898,550
– –
FUSN
7
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$39.3M 5.1%
3,670,516
– –
PHGE icon
8
BiomX
PHGE
$1.93M
$15.2M 1.97%
11,228
– –
ACET icon
9
Adicet Bio
ACET
$75.7M
$9.54M 1.23%
45,559
+4,142
+10% +$951K
PHAS
10
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$5.56M 0.72%
1,607,044
– –
ALDX icon
11
Aldeyra Therapeutics
ALDX
$94.7M
$4.69M 0.61%
394,834
-200,000
-34% -$2.3M
SENS icon
12
Senseonics Holdings Inc
SENS
$255M
$1.3M 0.17%
24,613
-1,669
-6% -$94.6K
CSLT
13
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$1.23M 0.16%
811,295
– –
TCON
14
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$691K 0.09%
4,200
– –
GYRE icon
15
Gyre Therapeutics
GYRE
$662M
$337K 0.04%
8,927
– –
CALC icon
16
CalciMedica
CALC
$11.5M
$275K 0.04%
+3,539
New +$1.06M
LUNG icon
17
Pulmonx
LUNG
$53.2M
$258K 0.03%
5,639
– –

Similar funds

NNP
Nachman Norwood & Parrott Greenville, South Carolina $984M AUM 33.8% 1-Year Est. Return
BAWC
Black-and-white Capital Los Angeles, California $967M AUM 94.03% 1-Year Est. Return
RP
RR Partners New York $929M AUM 110.28% 1-Year Est. Return
NIA
Northstar Investment Advisors Denver, Colorado $755M AUM 37.8% 1-Year Est. Return
SCM
Snow Capital Management Sewickley, Pennsylvania $703M AUM 76.26% 1-Year Est. Return
EMG
Ellington Management Group Old Greenwich, Connecticut $676M AUM 23.65% 1-Year Est. Return
APA
Allegiant Private Advisors Sarasota, Florida $618M AUM
HFA
Hoover Financial Advisors Malvern, Pennsylvania $562M AUM 37.9% 1-Year Est. Return

Johnson & Johnson Innovation - JJDC's Q1 2021 Portfolio in Review

As of Q1 2021, Johnson & Johnson Innovation - JJDC held 17 positions worth $772M, down 0.43% from $775M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Johnson & Johnson Innovation - JJDC deployed $45.1M of net new capital in Q1 2021, opening 2 new positions and adding to 1 existing holding. Its largest new stake was Vor Biopharma: 53,733 shares worth $46.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Aldeyra Therapeutics, an estimated $2.3M trimmed.

  • Johnson & Johnson Innovation - JJDC's largest Q1 2021 buy was Vor Biopharma: 53,733 shares worth $46.3M.
  • Johnson & Johnson Innovation - JJDC added most to Adicet Bio in Q1 2021, an estimated $951K increase.
  • Johnson & Johnson Innovation - JJDC's biggest Q1 2021 reduction was Aldeyra Therapeutics, cutting an estimated $2.3M.
  • Johnson & Johnson Innovation - JJDC's ten largest holdings make up 99% of its $772M portfolio in Q1 2021.
  • Johnson & Johnson Innovation - JJDC opened 2 new positions and closed 0 in Q1 2021.
  • Johnson & Johnson Innovation - JJDC's portfolio value fell 0.43% quarter-over-quarter to $772M.

Based on Johnson & Johnson Innovation - JJDC's 13F filing for Q1 2021, filed 6 May 2021.